IMMU - Immunomedics, Inc.
| Previous Close | 18.28 |
| Open | 17.84 |
| Bid | 17.90 x 4000 |
| Ask | 17.92 x 800 |
| Day's Range | 17.18 - 18.00 |
| 52 Week Range | 11.59 - 22.22 |
| Volume | 554,330 |
| Avg. Volume | 2,278,242 |
| Market Cap | 3.822B |
| Beta (5Y Monthly) | 2.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.77 |
| Earnings Date | Oct 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.82 |
- Benzinga
7 Blockbuster Drugs Expected To Be Launched In 2020
Biotech stocks had a fairly decent run in 2019, thanks to record deal flow , several path-breaking innovation in drug research & development and the positive broader market sentiment. New molecular entity ...
- TipRanks
3 “Strong Buy” Biotech Stocks That Can Inject a Healthy Dose of Upside
Biotech stocks require only a few select indicators to send a share price soaring, or conversely, to cause it to tumble mercilessly down the charts. An FDA decision or results from a clinical trial have the ability to impact the stock’s direction either way, often dramatically so.On the Street, though, the key is to see beyond the noise and recognize the inherent future potential a company presents. Ignore the price for the moment and concentrate on value, is an oft repeated mantra. Is the company on its way to solving previously solution-free problems? Is it cash strapped or financially secure? Does it have further catalysts down the line? All of these are issues that need to be considered when investing in a stock, and certainly in the volatile world of biotechs.Using TipRanks’ Stock Screener, we were able to zero in on 3 promising tickers in the biotech sector which the analysts think are ready to gain value in 2020. All three present serious upside potential, and what’s more, all currently boast a “Strong Buy” consensus rating from the Street. Let’s read the data.Immunomedics (IMMU)If you’re going to take your time to get something right, then you might as well really take your time. After almost 40 years of failed attempts and languishing in a perpetual development stage, Immunomedics might finally be on its way to getting a treatment to market.This biotech develops monoclonal antibody-based products for the treatment of cancer. The aforementioned almost-ready-to-launch drug is sacituzumab govitecan, a treatment for metastatic triple-negative breast cancer (TNBC), which combines a cancer-targeting antibody with an antitumor drug. The treatment is to be used as a “final attempt” drug following the failure of two previous therapies.Immunomedics was handed the dreaded CRL (complete response letter) from the FDA following its application last year after concerns not specifically related to the drug, but to “chemistry, manufacturing, and control” issues at the company’s manufacturing plant were raised. The concerns were addressed by IMMU and an application was resubmitted last month.Hopes are high as results from the drug’s clinical trials were better than those exhibited for chemotherapy treatments in second-line settings; Sacituzumab exhibited a 33% success rate in the third-line setting and progression free survival was 5.5 months. Chemo regime rates are in the mid-teens in both cases. The drug is also being studied as a potential early line treatment, too, and if it gets approval this year, expect Immunomedics’ share price to soar in 2020.H.C. Wainwright’s Ram Selvaraju is bullish on the cancer fighter. The 5-star analyst said, "We continue to believe that sacituzumab should potentially reach the market in early 3Q20 given the following: (1) the FDA previously reviewed sacituzumab's efficacy and safety profile and Immunomedics had a product label in hand, while the approval was solely subject to chemistry, manufacturing, and controls (CMC) review; (2) the issue cited in the Complete Response Letter (CRL) received in January 2019 was specifically CMC-related; (3) sacituzumab's clinically meaningful incremental efficacy benefit in third-line mTNBC relative to well-established historical controls; and (4) Immunomedics has had extensive dialog with FDA reviewers prior to the previous BLA submission, during the review and after the CRL."Selvaraju, therefore, maintained his Buy rating on IMMU. The analyst’s confidence is reflected by a raise of his price target: from $26 to $31, as it happens. The new target implies potential upside of 63%. (To watch Selvaraju’s track record, click here)The Street appears equally confident in IMMU’s future potential; 4 Buy ratings add up to a Strong Buy consensus rating. With an average price target of $28, the analysts believe Immunomedics can add 47% to its share price over the coming year. (See Immunomedics stock analysis on TipRanks) Revance Therapeutics (RVNC)After a disappointing 2019, which saw Revance’s share price drop by more than 18%, the neuromodulator-focused biotech has started 2020 with a bang; Revance stock is up by 38% year-to-date.So, what’s all the fuss about, then? The biotech recently secured a licensing deal with Swiss company, Teoxane Laboratories, for the exclusive US rights to its platform of hyaluronic-acid dermal fillers. These include the FDA-approved RHA 2, RHA 3, and RHA 4. Revance will issue 2.5 million shares to Teoxane in exchange for the rights. Additionally, the company also received the rights to RHA 1, a fourth filler currently in clinical trials, with data expected in 2021.There’s more to come in 2020, too. Revance recently filed a Biologics License Application (BLA) for DAXI, a long-lasting formulation of a neurotoxin treatment of moderate to severe glabellar (frown) lines. Revance expects an FDA approval for the treatment in 2H20, following which DAXI could potentially provide serious competition to a market dominated by Allergan's Botox.Needham’s Serge Belanger believes RVNC’s product line has the potential to take a big chunk out of the $5 billion neuromodulator market. The 4-star analyst said, “We view RVNC's DaxibotulinumtoxinA (Daxi), which has consistently demonstrated higher efficacy and longer duration than any of the current neuromodulators, as the first major neurotoxin innovation in the last 30 years. The recent BLA filing of Daxi in late November kicked off what should be a transformational period for RVNC in 2020 that include a potential Mylan opt-in for a biosimilar collaboration, numerous data readouts, most notably the pivotal Phase 3 cervical dystonia (CD) trial readout that will establish the product's therapeutic potential, and a likely first FDA approval and launch in 2H20.”Where does this leave Belanger, then? In the Buy section, naturally. Along with the reiteration, Belanger kept his price target at $32. This implies potential gains of 42% over the next 12 months. (To watch Belanger’s track record, click here)The frown warrior gets no frowns from the Street, either. 8 Buys spell out a unanimous Strong Buy consensus rating for Revance. With an average price target of $32.88, the upside potential comes in at 46%. (See Revance stock analysis on TipRanks) Theravance Biopharma (TBPH)Theravance Biopharma has a diversified portfolio focusing on therapies in a number of areas; these include respiratory, gastrointestinal, cardiovascular, infectious, inflammatory, and immunology diseases. Although the company has hit its targets over the last couple of years, the stock’s performance has not followed accordingly. Is this about to change in 2020?Theravance already has an FDA approved drug on the market. Yupelri, a treatment for chronic obstructive pulmonary disease (COPD) that came as the result of a partnership with Mylan, gained approval from the FDA at the end of 2018. According to Theravance, throughout the first three quarters of 2019, roughly 21,000 patients received the drug.The company also has additional revenue streams. GlaxoSmithKline provides a royalty of between 5.5% to 8.5% for global net sales of Trelegy Ellipta. The COPD treatment is approved in 38 countries and has snapped up a 31% market share since September 2017. Theravance also sold its drug for life-threatening bacterial infections, Vibativ, to Cumberland Pharmaceuticals. The deal included a $20 million upfront payment plus royalties of up to 20% of U.S. net sales (capped at $100 million).With further drug candidates in the pipeline, Cantor Fitzgerald’s Louise Chen believes Theravance is “undervalued and underappreciated.” Highlighting the commercial launches of Trelegy Ellipta and Yupelri, its success in executing its business objectives in 2019, and the company’s “best-in-class” pipeline, the analyst thinks TBPH has “strong momentum” heading into 2020.Accordingly, then, Chen reiterated an Overweight rating on TBPH and kept her price target of $55 as is. Should the target be met, investors will be taking home a very healthy 118% increase over the coming months. (To watch Chen’s track record, click here)Currently, Theravance has a Strong Buy consensus rating from the Street. The breakdown presents 5 Buys and 1 Hold rating. At $36.67, the average price target presents possible upside of 45%. (See Theravance stock analysis on TipRanks)
- Zacks
Immunomedics Sees Hammer Chart Pattern: Time to Buy?
Immunomedics has been struggling lately, but the selling pressure may be coming to an end soon.
- TheStreet.com
Responding to a Subscriber Question About Immunomedics
One subscriber asked about what I thought of Immunomedics . The company is a clinical-stage biopharmaceutical company that is "developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases". In this daily bar chart of IMMU, below, we can see three tests of the $12 area over the past year.
- Barrons.com
After Nearly 40 Years, a Biotech Company Readies Its First Product
Immunomedics, a New Jersey biotech firm, says the Food and Drug Administration will begin reviewing its application to market an antibody treatment for breast cancer.
- Zacks
FDA Accepts Immunomedics' BLA Refiling for Breast Cancer Drug
The FDA accepts Immunomedics' (IMMU) BLA resubmission for sacituzumab govitecan to treat patients with metastatic triple-negative breast cancer, having received at least two prior therapies.
- Benzinga
The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 26.) Aimmune Therapeutics Inc (NASDAQ: AIMT ...
- GlobeNewswire
Immunomedics Announces FDA Acceptance for Filing of Biologics License Application Resubmission for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer
Prescription Drug User Fee Act (PDUFA) target action date set for June 2, 2020 MORRIS PLAINS, N.J., Dec. 26, 2019 -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the.
- Zacks
4 Drug/Biotech Outperformers That May Lose Steam in 2020
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
- Barrons.com
Surging Biotech Stocks Kodiak Sciences, Immunomedics See Largest Holders Buy More
Baker Bros. Advisors paid $87.5 million for more Kodiak stock, while Avoro Capital paid $35 million for additional Immunomedics shares.
- Zacks
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
- Schaeffer's Investment Research
Signal Says Drug Stock Not Done Climbing
The drug stock is ripe for a short squeeze, too
- GlobeNewswire
Immunomedics Announces Closing of Public Offering of Common Stock
The total number of shares of common stock sold was 16,428,572, composed of 14,285,715 shares of common stock initially offered and an additional 2,142,857 shares of common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, in each case at a public offering price of $17.50 per share. The total net proceeds from the offering for Immunomedics are estimated to be approximately $272 million, after deducting underwriting discounts and commissions but before deducting other estimated offering expenses payable by the Company.
- Insider Monkey
Did Hedge Funds Drop The Ball On Immunomedics, Inc. (IMMU) ?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
- GlobeNewswire
Immunomedics Announces Pricing of Public Offering of Common Stock
In addition, Immunomedics has granted the underwriters a 30-day option to purchase up to 2,142,857 additional shares of common stock. Immunomedics intends to use the net proceeds from this offering primarily to accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in metastatic triple-negative breast cancer, continue to expand the clinical development programs for sacituzumab govitecan, invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), continued scale-up of manufacturing and manufacturing process improvements, as well as for working capital and general corporate purposes. Goldman Sachs & Co. LLC, BofA Securities, Cowen and Company, LLC and Jefferies LLC are acting as joint book-running managers for the offering.
- Zacks
Immunomedics Resubmits Application for Breast Cancer Drug
Immunomedics (IMMU) resubmits BLA to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer, who have received at least two prior therapies.
- Benzinga
The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares ...
- GlobeNewswire
Immunomedics Announces Proposed Public Offering of Common Stock
In addition, Immunomedics expects to grant the underwriters a 30-day option to purchase up to an aggregate of an additional $37,500,000 of shares of common stock sold in connection with the offering at the public offering price. Immunomedics intends to use the net proceeds from this offering primarily to accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in metastatic triple-negative breast cancer, continue to expand the clinical development programs for sacituzumab govitecan, invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), continued scale-up of manufacturing and manufacturing process improvements, as well as for working capital and general corporate purposes. Goldman Sachs & Co. LLC, BofA Securities, Cowen and Company, LLC and Jefferies LLC are acting as joint book-running managers for the offering.
- GlobeNewswire
Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan
MORRIS PLAINS, N.J., Dec. 03, 2019 -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug.
- Zacks
Implied Volatility Surging for Immunomedics (IMMU) Stock Options
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
- Benzinga
The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More
Biotech stocks experienced some momentum last week amid a few clinical readouts. Karuna Therapeutics Inc (NASDAQ: KRTX ), which went public in June, was among the biggest gainers of the week on a positive ...
- GlobeNewswire
Immunomedics to Present at Upcoming Healthcare Conferences
MORRIS PLAINS, N.J., Nov. 13, 2019 -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug.
- Zacks
Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up
Clovis (CLVS) reports encouraging third-quarter 2019 results. The company tightens guidance for product sales in 2019.
- Thomson Reuters StreetEvents
Edited Transcript of IMMU earnings conference call or presentation 30-Oct-19 9:00pm GMT
Q3 2019 Immunomedics Inc Earnings Call
